Compare Organon & Co. Common Stock (OGN) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Teucrium Wheat Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Teucrium Wheat Fund trades at $24.38 (market cap $274.59M). The key difference: Organon & Co. Common Stock is far larger — about 13.2× Teucrium Wheat Fund's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Teucrium Wheat Fund for 42 Days on average.
| OGN | WEAT | |
|---|---|---|
Market Cap | $3.62B | $274.59M |
Volume | 2,892,999 | 203,622 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $13.81 | $28.00 |
52-Week Low | $5.70 | $19.88 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
WEAT trades at $24.28, down 0.74% today, with a bearish technical signal from moving averages. Recent news highlights a 25% year-to-date gain as of July 2026, driven by wheat market dynamics, though inflation concerns persist. Key support is at $24, with resistance at $25. The absence of fundamental ratios like P/E and P/S in the data limits valuation clarity, but the ETF's performance is tied to agricultural commodity trends.
The outlook is cautious due to bearish technical indicators and macroeconomic inflation pressures. Opportunities exist if wheat prices rally, but risks include commodity volatility and Federal Reserve policy impacts. Investors should weigh the ETF's lack of traditional company fundamentals against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
